Close menu




March 13th, 2024 | 07:30 CET

HelloFresh, Royal Helium, Evotec - Rebounds in sight

  • Mining
  • Helium
  • Biotechnology
  • Food
Photo credits: pixabay.com

Despite all the various challenges in today's world, such as geopolitical tensions or inflation, the stock market indices have managed to climb upwards. Investors are faced with a crucial question: Where is the hidden value in a market that has already broken many records? The answer could lie in those stocks that have so far stood on the sidelines of the great rally - the silent but potentially strong performers waiting for their rebound. This strategy shifts the focus away from the usual suspects who have already posted substantial gains to stocks that are ready to initiate their own rebound, potentially unlocking significant value for patient investors in the process. We have identified three such candidates.

time to read: 4 minutes | Author: Armin Schulz
ISIN: HELLOFRESH SE INH O.N. | DE000A161408 , ROYAL HELIUM LTD. | CA78029U2056 , EVOTEC SE INH O.N. | DE0005664809

Table of contents:


    HelloFresh - Stock market crash following revision of earnings expectations

    HelloFresh's share price fell by a substantial 45% after the Company revised its financial targets for 2025 downwards to EUR 10 billion in sales and EUR 1 billion in EBITDA. This move raised concern among investors, leading to substantial sell-offs and marking the largest share price decline in the Company's history. Analysts saw this revision as further evidence of the challenges facing the Company, especially after previous forecast adjustments. The Company saw substantial growth during the COVID-19 era, with the stock reaching over EUR 95 at its peak. Since then, it has been on a downward trend.

    Sales for 2023 are expected to be around EUR 7.6 billion, similar to the previous year. The adjusted EBITDA is projected to be EUR 448 million, compared to EUR 477 million in the previous year. While these figures align with forecasts, they fall short of representing significant growth. The Company is now forecasting an adjusted operating profit of EUR 350 to 400 million for 2024. These new targets are significantly lower than the previous assumptions. One of the reasons could be the delay in the expansion of a production facility in the US. With the "Ready-to-Eat" brand, the Company wanted to establish a second mainstay in the Ready-to-Eat segment, which is a growing segment for the Company.

    However, the demand for pre-portioned meal kits is declining. New customers are only attracted by heavy discounts. The Company is faced with the task of consolidating its core business while effectively developing new growth areas. While management grapples with these strategic issues, it remains to be seen how HelloFresh can strengthen its position in the market and regain investor confidence. However, the sharp fall in the share price could present the Company as an interesting takeover candidate. The share is currently trading at EUR 7.13, giving it a market capitalization of just under EUR 1.2 billion.

    Royal Helium - Announces company update

    At the end of 2023, the explorer Royal Helium evolved into a producer of industrial gas. While this transformation may not yet be evident from the figures to date, it is expected to change with the announcement of the figures for the first quarter. The Company, with extensive licenses and lease agreements covering over 1 million hectares in South Saskatchewan and Southeast Alberta, spread across more than 15 potential helium fields, holds significant growth opportunities in a globally undersupplied market. Due to the critical nature of this resource, the Canadian government is supporting the Company with a CAD 3 million interest-free loan to facilitate further upgrades to the Steveville helium processing facility in Alberta.

    On February 28, the Company announced its development plans for its four key exploration projects. Royal Helium is focusing its development activities on the completion and testing of existing wells in the Val Marie, Ogema and Steveville areas and the drilling of new wells on the 40-Mile project in Alberta. First, there is the Val Marie project, which covers 13,000 hectares and has the highest helium levels ever recorded by the Company in the initial drill hole. The Ogema property spans 27,000 hectares and has two drill holes completed so far. The 40-Mile project covers approximately 3,100 hectares and features a historically high-grade helium well. Following the drilling results, the Company intends to decide on the next location for processing.

    The experience gained from the Steveville production facility provides a proof of concept and will enable the next facility to be implemented more quickly. A potential untapped zone has been identified in Steveville and will now be tested. If the results are positive, the life of the Steveville project could be increased by 33%. With a third well, a production buffer could be created so that production could be maintained at 100% should maintenance work be required on one of the other two producing wells. The share has yet to price in the good news flow and is trading at CAD 0.175.

    Evotec - No turnaround yet, despite the good news

    After the surprising resignation of the then-CEO Werner Lanthaler, Evotec's share price plummeted and has not recovered. The situation was explained in more detail in a conference call. Lanthaler had asked the Supervisory Board to terminate his employment contract at the end of 2023. The Supervisory Board complied with this on January 3. At the same time, Lanthaler disclosed a series of insider transactions, which the Company reported immediately. The Company then reviewed its processes in this regard. Mr. Lanthaler will no longer be involved in any of the Company's activities.

    Evotec is focusing on strategic partnerships, such as a collaboration with Claris Ventures. Companies in Claris' portfolio benefit from easy access to Evotec's extensive pre-clinical, clinical development, and manufacturing capabilities. This agreement builds on a previously successful collaboration between Evotec and IAMA, a company in Claris' portfolio. Just-Evotec Biologics and Advanced BioScience Laboratories are expanding their collaboration to develop innovative therapies against HIV.

    Despite these positive developments and supportive analyst ratings, the Company's shares remain under pressure. The investment community awaits tangible progress and a worthy successor to Lanthaler as Evotec seeks to regain its confidence and consolidate its position in the biotech industry. After all, the short sellers have largely exited the stock, which is a positive sign. The share has been forming a bottom around EUR 12.70 and EUR 13.00 for a few days. The share is currently trading at EUR 13.07.


    Each of the three candidates has the opportunity to turn things around. HelloFresh has an operationally positive business, a claim not many online companies can make. A possible takeover could provide a boost. Royal Helium is now a helium producer and can turn other gases from extraction into money. The public is likely to take notice after the first-quarter figures. Evotec has only been dragged down by the departure of the CEO. Operationally the Company is making good progress. A turnaround is likely only a matter of time.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


    Der Autor

    Armin Schulz

    Born in Mönchengladbach, he studied business administration in the Netherlands. In the course of his studies he came into contact with the stock exchange for the first time. He has more than 25 years of experience in stock market business.

    About the author



    Related comments:

    Commented by André Will-Laudien on May 13th, 2025 | 07:20 CEST

    Defense out - Time to buy commodities! Hensoldt, Globex Mining, Barrick, Mutares, and Steyr

    • Mining
    • Gold
    • Defense
    • Investments

    That is how quickly market darlings can fall out of favor. Just last week, Rheinmetall & Co. were hitting record highs, but as of Monday, the euphoria came to a sudden halt. Trump agreed with China on lower tariffs, and Volodymyr Zelenskyy will travel to Turkey on Thursday to sit down with Russia's aggressor, Vladimir Putin. At the moment, this is still hard to believe. For the capital markets, however, this means a shift: out of defense and into high-tech and automotive stocks, the biggest winners of recent hours. The whole thing could be seen as a healthy rotation, as the major indices are at record levels, while tech and automotive stocks have corrected significantly in recent weeks. Once again, the cards are being reshuffled. For Globex Mining, the setback is suitable for medium-term follow-up purchases.

    Read

    Commented by Nico Popp on May 13th, 2025 | 07:10 CEST

    The fight against cancer as a billion-dollar opportunity: BioNTech, Merck, and Vidac Pharma

    • Biotechnology
    • Biotech
    • Pharma

    Cancer is the scourge of our time. However, significant progress has already been made in recent years. In addition to significantly improved traditional therapies, individualized treatment approaches such as immunotherapy are repeatedly proving successful in curing patients. This trend is set to continue. Experts such as the investors at Candriam and market researchers at Spherical Insights foresee enormous growth – the market for cancer drugs could see double-digit annual growth by the 2030s. Market leaders such as BioNTech and Merck, as well as insider tips like Vidac Pharma, stand to benefit.

    Read

    Commented by Armin Schulz on May 13th, 2025 | 07:00 CEST

    When returns meet security: Why Almonty Industries is suddenly everyone's darling!

    • Mining
    • Tungsten
    • Defense
    • Investments

    In 2025, the world looks at a map full of conflicts: tensions are escalating in Ukraine, the Middle East, and along new geopolitical fault lines in Asia and Africa. Hopes for peace are giving way to a reality of rearmament and militarization. This dynamic is fueling the defense industry. But its boom depends on an inconspicuous metal: tungsten. With its unique heat resistance and density, it is irreplaceable for armor-piercing ammunition, missiles, and high-performance alloys. While China dominates the global market, a Canadian company is stepping into the spotlight: Almonty Industries. With the revival of the legendary Sangdong mine in South Korea and strategic partnerships, Almonty could become a key player for the West.

    Read